Zydus Cadila gets nod for Zonisamide Capsules from US FDA

Mumbai, Oct 17 (UNI) Cadila Healthcare Ltd today announced it has received approval from the US FDA to market Zonisamide Capsules in different strengths of 25 mg, 50 mg and 100 mg.

Announcing this in a notice to BSE, the company said the drug falls in the anti-epileptic segment. The branded sales of Zonisamide Capsules in the US market was estimated at USD 178 mn in 2005 as per IMS. The company will market the drug through its US subsidiary Zydus Pharmaceuticals (USA) Inc.

This marks the l7th ANDA approval for the group since the commencement of filing process in FY 2003-04. So far the group has filed 41 ANDAs and 45 DMFs.

UNI SN PM VKG1940